EIF2A antibody (Eukaryotic Translation Initiation Factor 2A, 65kDa) (AA 448-576)

Details for Product anti-EIF2A Antibody No. ABIN1724933
Antigen
Epitope
AA 448-576
15
13
12
12
11
9
8
8
8
7
4
4
3
2
2
2
2
2
2
1
1
1
1
1
1
Reactivity
Human, Mouse (Murine), Monkey, Rat (Rattus)
140
78
75
8
5
3
2
2
1
1
1
1
1
1
Host
Mouse
120
21
Clonality (Clone)
Monoclonal ()
Conjugate
This EIF2A antibody is un-conjugated
7
5
5
5
4
4
3
3
3
2
2
2
2
2
2
2
2
Application
Flow Cytometry (FACS), Immunohistochemistry (IHC), ELISA, Western Blotting (WB)
99
71
50
29
24
20
17
4
4
2
1
1
Options
Immunogen Purified recombinant fragment of human EIF2A (AA 448-576) expressed in E. Coli.
Clone 3A7B11
Isotype IgG1
Purification Purified
Antigen
Alternative Name EIF2A (EIF2A Antibody Abstract)
Background EIF2A is a 65-kD protein that catalyzes the formation of puromycin-sensitive 80S preinitiation complexes.
Molecular Weight 65 kDa
Gene ID 83939
HGNC 83939
Pathways Ribonucleoprotein Complex Subunit Organization, ER-Nucleus Signaling, Hepatitis C, Methionine Biosynthetic Process, Ribosome Assembly
Application Notes ELISA: 1:10000, WB: 1:500 - 1:2000, IHC: 1:200 - 1:1000, FCM: 1:200 - 1:400
Restrictions For Research Use only
Format Liquid
Buffer PBS with 0.05 % sodium azide.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C,-20 °C
Storage Comment 4°C, -20°C for long term storage
Supplier Images
Image no. 1 for anti-Eukaryotic Translation Initiation Factor 2A, 65kDa (EIF2A) (AA 448-576) antibody (ABIN1724933) Immunohistochemical analysis of paraffin-embedded bladder cancer tissues using EIF2A ...
Image no. 2 for anti-Eukaryotic Translation Initiation Factor 2A, 65kDa (EIF2A) (AA 448-576) antibody (ABIN1724933) Immunohistochemical analysis of paraffin-embedded cervical cancer tissues using EIF2A...
Product cited in: Yerlikaya, DoKudur: "Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells." in: Molekuliarnaia biologiia, Vol. 44, Issue 5, pp. 859-66, 2010 (PubMed).

Schewe, Aguirre-Ghiso: "Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy." in: Cancer research, Vol. 69, Issue 4, pp. 1545-52, 2009 (PubMed).